Imagine having access to essential funding for your business to develop innovative drugs aimed at preventing or treating Alzheimer’s disease. This opportunity is designed specifically for companies like yours, where you can secure funding for critical research activities such as drug formulation, pharmacokinetics, and early clinical testing. With no set funding limits, you have the flexibility to apply for what you truly need to support your development efforts.

Applying to this program means you can accelerate your research while reducing financial burdens. Your business could benefit from valuable resources that help you make meaningful advancements in healthcare. By participating, you not only enhance your potential for growth and innovation but also contribute to a cause that can impact millions of lives.

Overall, this program is a unique chance to transform your ideas into reality without overwhelming financial constraints. It’s straightforward and accessible—allowing you to focus on what you do best: creating solutions that matter.

Type of Financing

This program offers grant funding specifically tailored for the development of therapies targeting Alzheimer's disease. Grants do not require repayment, providing you with financial support without the burden of debt.

Repayment Terms and Fees

Since this is a grant, there are no repayment terms or interest rates involved. Additionally, there are no hidden fees associated with the program, making it straightforward and accessible for your business.

Eligible Expenses

Funds can be used for a variety of expenses related to your project, such as:

• Medicinal chemistry
• Pharmacokinetics (PK)
• ADMET studies (Absorption, Distribution, Metabolism, Excretion, Toxicology)
• Efficacy evaluation in animal models
• Biomarker development
• Formulation development
• Chemical synthesis adhering to Good Manufacturing Practices (GMP)
• Investigational New Drug (IND) enabling studies
• Initial Phase I clinical testing

Ineligible Expenses

Please note that funds cannot be used for:

• Basic research on disease mechanisms or drug action
• Development of risk, diagnostic, prognostic, predictive, and prevention biomarkers
• Non-pharmacological interventions (like exercise, diet, cognitive training)
• Repurposed drugs and combination therapies
• Discovery activities such as high-throughput screening and hit optimization
• Stand-alone clinical trials

This clarity on what you can and cannot use the funds for is essential to ensure a smooth application process.

• Location: Available across the country.
• Sectors: Open to all sectors.
• Employee Count:
  • No minimum number of employees required.
  • No maximum number of employees required.
• Company Revenue:
  • No minimum revenue qualifications.
  • No maximum revenue qualifications.
• Legal Structure: All legal structures are applicable.
• Profit Structure: All profit structures are applicable.

Disqualifications:

• Research on basic mechanisms of disease or mechanisms of drug action is not responsive.
• Development of risk, diagnostic, prognostic, preventive biomarkers, devices, non-pharmacological interventions, repurposed drugs, combination therapies, or discovery activities is not eligible.
• Stand-alone clinical trials are not included.

This program aims to support the early stages of developing new drugs to prevent, slow, or treat Alzheimer’s disease. You can receive funding for various activities related to developing these therapies. This includes essential research such as medicinal chemistry, toxicity studies, and early clinical trials.

The funding is versatile and can be used for activities like developing effective drug formulations and conducting initial testing in animals and humans. It empowers you to focus on creating innovative solutions in the healthcare sector.

There’s no set amount of funding, so your business has the flexibility to apply for what you need. This program offers you a chance to make a real impact in the field while potentially securing resources to assist in your development efforts.